HEALTH: Summary of Nov 11, 2026

By · Published on

Illustration of glass medicine vials
AI-generated illustration; does not depict the actual event.

American regulators ordered new warnings on GLP-1 drugs, researchers linked breast cancer chemotherapy to faster ageing, doctors cautioned teenagers against a cancer drug taken to gain height, the WHO reported cholera deaths this year, and vaccine partners met officials in Nigeria’s Kaduna State.

FDA orders warnings on GLP-1 drugs over a rare cause of sudden vision loss

The US Food and Drug Administration has told the makers of GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy, or NAION. The disorder occurs when blood flow to the optic nerve is cut off, and it can cause painless loss of vision in one eye that may be permanent. The agency said its review found an increased risk of rare NAION events in patients taking the medicines.

The review covered reports of side effects and studies involving more than 134,000 patients, and found about six cases a year per 100,000 people on GLP-1 drugs, compared with about four among those on a placebo or other diabetes treatments. Novo Nordisk, which makes Ozempic and Wegovy, said the data did not establish cause and effect, and Eli Lilly said it was evaluating the update. The American Academy of Ophthalmology said any added risk appeared small and urged patients not to stop treatment without medical advice.

GLP-1 receptor agonists are medicines that lower blood sugar and reduce appetite. They were first developed to treat type 2 diabetes, and some have since been approved for obesity, including semaglutide, sold as Wegovy, and tirzepatide, sold as Zepbound. Anterior ischemic optic neuropathy typically causes sudden, painless loss of sight that develops over hours to days, and there is no recognised treatment that can reverse it. When it appears in people under 50, doctors are advised to look for other causes.


Model suggests breast cancer chemotherapy may speed up biological ageing

Researchers at Georgetown University’s Lombardi Comprehensive Cancer Center say chemotherapy for breast cancer may accelerate biological ageing and raise the risk of early death, according to new modelling. Patients given the most aggressive drugs could lose more than 9 years of healthy life, and the effects may not show until later, the researchers said on Tuesday. Swarnavo Sarkar, of the centre’s Institute for Cancer and Aging Research, said the treatment increases the number of senescent cells, which stop dividing but resist dying.

The model drew on years of public data to estimate chemotherapy-related ageing in 400 million women aged 30 to 79, and examined levels in the blood of the protein p16, a common marker of senescent cells. The team is studying whether exercise and medicines developed for other purposes could slow or reverse the effect, and plans to look next at radiotherapy and other treatments. Female breast cancer survivors form the largest group among the 18.6 million cancer survivors in the United States, according to the American Cancer Society.

Cellular senescence is the point at which cells permanently stop dividing. In the early 1960s, the scientists Leonard Hayflick and Paul Moorhead found that normal human cells grown in the laboratory reach a limit of about 50 population doublings before they become senescent, a boundary now known as the Hayflick limit. Senescence can be triggered by many kinds of stress, including damage to DNA, and senescent cells are thought to contribute to frailty, muscle loss and other diseases linked to ageing.


Doctors warn teenagers against a bladder cancer drug taken to grow taller

Doctors are warning about an online trend known as heightmaxxing, in which teenagers, mostly boys, take erdafitinib, a prescription drug approved for advanced bladder cancer, in the hope of growing taller. The medicine is reportedly being obtained on the black market after social media discussions suggested it could add height. Its maker, Johnson & Johnson, said the drug had never been approved to stimulate growth and that its safety and effectiveness had not been established for any child or adolescent.

Medical reports have described unexpected growth spurts in children given the drug for brain tumours, including a 2024 study of two young patients and a case in which a teenager grew more than 5 inches but developed serious skeletal problems. Stephanie Widmer, an emergency physician in New York, said the drug can cause permanent vision damage and high phosphate levels, and that once growth plates close at the end of puberty no medicine can reopen them. Jessica Gray, a family doctor in Texas, warned of fractures.

Erdafitinib, sold under the brand name Balversa, blocks fibroblast growth factor receptors, proteins that help control how some tumour cells grow and multiply. It was discovered by Astex Pharmaceuticals and licensed to Janssen Pharmaceuticals for development. The US regulator first approved it in April 2019 for advanced bladder cancer with certain genetic changes that had progressed after platinum-based chemotherapy, and in January 2024 it granted full approval for adults with advanced or metastatic urothelial cancer carrying susceptible gene alterations.


WHO says cholera has killed more than 3,000 people so far this year

More than 3,000 people around the world have died of cholera in 2026 so far, the World Health Organization said on Tuesday, adding that its target of reducing global cases by 90 per cent by 2030 was still within reach. Lorenzo Pezzoli, the agency’s lead for epidemic-prone bacterial diseases, said deaths had fallen in the first nine months of 2026 compared with last year, but that nearly nine out of 10 of those who died were in Africa.

The disease killed nearly 7,900 people in 2025, the deadliest year since 1999, Pezzoli said. The agency warned that the current El Nino pattern could make outbreaks worse, because cholera spreads with both floods and water shortages. Last year an international coordinating group approved the supply of 71 million vaccine doses funded by Gavi. About 90 per cent of last year’s cases and deaths were in seven countries: Nigeria, Angola, Sudan, South Sudan, Yemen, Bangladesh and the DR Congo.

Cholera is an infection of the small intestine caused by some strains of the bacterium Vibrio cholerae. It is estimated to affect 3 to 5 million people around the world each year and to cause between 28,800 and 130,000 deaths annually. There have been seven cholera pandemics to date, and the most recent began in 1961 and continues today. The disease can spread through water and food contaminated with sewage, including shellfish harvested in polluted waters, and it is easily treated if care is given quickly.


Vaccine partners and Kaduna State target children missing routine immunisation

The Gavi vaccine alliance, the WHO, UNICEF and other partners have agreed to work with the government of Kaduna State in Nigeria to reduce the number of children missing routine vaccinations. After a visit by a delegation on Monday, Professor Bello Jamoh, head of the state’s primary health care board, said the rise in children who have received no vaccines at all was a major concern, linked to immunity gaps and repeated outbreaks of diseases such as diphtheria.

The delegation was led by Thabani Maphosa, Gavi’s chief country delivery officer, who said insecurity was among the factors limiting access to health care and called for stronger coordination. Garba Rufai of Nigeria’s National Primary Health Care Development Agency said a recent outbreak in one community had reportedly killed five children, which had made it easier to persuade parents to vaccinate. Rownak Khan, UNICEF’s deputy representative in Nigeria, urged the state to fund the agreed plans.

Gavi, the Vaccine Alliance, is a public and private partnership that works to increase access to immunisation in poor countries and is the largest channel for donor money spent on vaccines. It says it has helped to immunise more than 760 million children and to prevent more than 13 million deaths, and diphtheria vaccine coverage in the countries it supports rose from 59% in 2000 to 81% in 2019. Kaduna State, in north-west Nigeria, is the third most populous state in the country.

In this topic